Allogene Therapeutics, Inc. (ALLO) Stock Analysis
A live, multi-source view of Allogene Therapeutics, Inc. (ALLO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Sector: Healthcare · Industry: Biotechnology · United States · 150 employees · allogene.com
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Allogene Therapeutics, Inc. (ALLO) last closed at $1.73 (the last completed close before that scan).
Technicals at the scan: RSI 35 (neutral territory), price -14.4% versus its 20-day average, 20-day versus 50-day average spread +2.5%, MACD histogram -0.04.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 79/100.
Next scheduled company event: in 56 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ALLO; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-08-25). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Earl Martin Douglas (0B/1S). Who is trading what
RapidTradeView pick record
ALLO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Allogene Therapeutics, Inc. (ALLO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ALLO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.